JP MORGAN/CALL/VERTEX PHARMACEUTICALS/440/0.1/17.01.25 | Market Closed - Börse Stuttgart 05:01:01 2024-07-05 am EDT | ||
| 6 EUR | -1.15% |
|
| Current month | -5.81% | ||
| 1 month | -13.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 6 | -1.15% |
| 24-07-04 | 6.07 | -4.56% |
| 24-07-03 | 6.36 | +3.08% |
| 24-07-02 | 6.17 | +1.15% |
| 24-07-01 | 6.1 | -4.24% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 05:01 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL795A |
| ISIN | DE000JL795A2 |
| Date issued | 2023-07-19 |
| Strike | 440 $ |
| Maturity | 2025-01-17 (196 Days) |
| Parity | 10 : 1 |
| Emission price | 2.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.51 € |
|---|---|
| Lowest since issue | 2.19 € |
| Spread | 0.3 € |
| Spread % | 4.55% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Warrants
- Warrant
